Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Arielle G. Bensimon, Zheng-Yi Zhou, Madeline Jenkins, Yan Song, Wei Gao, James Signorovitch, Clemens Krepler, Frank Xiaoqing Liu, Jingshu Wang & Raquel Aguiar-Ibáñez. (2019) Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. Journal of Medical Economics 22:10, pages 981-993.
Read now
Read now
Pol Specenier. (2016) Ipilimumab in melanoma. Expert Review of Anticancer Therapy 16:8, pages 811-826.
Read now
Read now
Articles from other publishers (32)
Yan Li, Xueyan Liang, Huijuan Li & Xiaoyu Chen. (2022) Atezolizumab plus bevacizumab versus nivolumab as first‐line treatment for advanced or unresectable hepatocellular carcinoma: A cost‐effectiveness analysis. Cancer 128:22, pages 3995-4003.
Crossref
Crossref
Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo & Xiaoyu Chen. (2022) Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan & Chongqing Tan. (2021) Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Chao Cai, Ismaeel Yunusa & Ahmad Tarhini. (2021)
Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of
BRAF V600
Variation Metastatic Melanoma
. JAMA Network Open 4:11, pages e2132262.
Crossref
Crossref
Mia Salans, Patrick Travis Courtney, Anthony Yip & James D. Murphy. (2021) Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma. Cancer Medicine 10:19, pages 6618-6626.
Crossref
Crossref
Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat & Virginie Nerich. (2020) Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunology, Immunotherapy 69:10, pages 1947-1958.
Crossref
Crossref
Arielle G. Bensimon, Zheng-Yi Zhou, Madeline Jenkins, Yan Song, Wei Gao, James Signorovitch, Clemens Krepler, Emilie Scherrer, Jingshu Wang & Raquel Aguiar-Ibáñez. (2020) An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clinical Drug Investigation 40:7, pages 629-643.
Crossref
Crossref
Claire Gorry, Laura McCullagh & Michael Barry. (2019) Transferability of Economic Evaluations of Treatments for Advanced Melanoma. PharmacoEconomics 38:2, pages 217-231.
Crossref
Crossref
Ahmad Tarhini, David McDermott, Apoorva Ambavane, Komal Gupte-Singh, Valerie Aponte-Ribero, Corey Ritchings, Agnes Benedict, Sumati Rao, Meredith M Regan & Michael Atkins. (2019)
Clinical and economic outcomes associated with treatment sequences in patients with
BRAF
-mutant advanced melanoma
. Immunotherapy 11:4, pages 283-295.
Crossref
Crossref
Abdulaali R. Almutairi, Nimer S. Alkhatib, Mok Oh, Clara Curiel-Lewandrowski, Hani M. Babiker, Lee D. Cranmer, Ali McBride & Ivo Abraham. (2019) Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatology 155:1, pages 22.
Crossref
Crossref
Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone, Joe Y. Chang, James W. Welsh & Charles R. Thomas. (2018) A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Sara Valpione, Sandro Pasquali, Luca Giovanni Campana, Luisa Piccin, Simone Mocellin, Jacopo Pigozzo & Vanna Chiarion-Sileni. (2018) Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine 16:1.
Crossref
Crossref
Valesca P. Retèl, Lotte M. G. Steuten, Marnix H. Geukes Foppen, Janne C. Mewes, Melanie A. Lindenberg, John B. A. G. Haanen & Wim H. van Harten. (2018) Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. BMC Cancer 18:1.
Crossref
Crossref
Frederick C. Morgan, Juanita Duran, Belen Fraile, Pritesh S. Karia, Jennifer Y. Lin, Patrick A. Ott, Emily Stamell Ruiz, David M. Wang, Yichen Zhang & Chrysalyne D. Schmults. (2018) A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. Journal of the American Academy of Dermatology 79:5, pages 921-928.
Crossref
Crossref
Ahmad Tarhini, Agnes Benedict, David McDermott, Sumati Rao, Apoorva Ambavane, Komal Gupte-Singh, Javier Sabater, Corey Ritchings, Valerie Aponte-Ribero, Meredith M Regan & Michael Atkins. (2018)
Sequential treatment approaches in the management of
BRAF
wild-type advanced melanoma: a cost–effectiveness analysis
. Immunotherapy 10:14, pages 1241-1252.
Crossref
Crossref
Margreet G. Franken, Brenda Leeneman, Anouk Jochems, Maartje G. Schouwenburg, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Alfonsus J.M. van den Eertwegh, Jan Willem B. de Groot, Koos J.M. van der Hoeven, Geke A.P. Hospers, Ellen Kapiteijn, Rutger Koornstra, Wim H.J. Kruit, Marieke W.J. Louwman, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Gerard Vreugdenhil, Michel W.J.M. Wouters, Michiel van Zeijl, John B.A.G. Haanen & Carin A. Uyl-de Groot. (2018) Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs 29:6, pages 579-588.
Crossref
Crossref
Luis Silva Miguel, Francisca Vargas Lopes, Bernardete Pinheiro, Jingshu Wang, Ruifeng Xu, James Pellissier & Pedro Almeida Laires. (2017) Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal. Value in Health 20:8, pages 1065-1073.
Crossref
Crossref
Darío Rubio-Rodríguez, Silvia De Diego Blanco, Maite Pérez & Carlos Rubio-Terrés. (2017) Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review. PharmacoEconomics 35:9, pages 879-893.
Crossref
Crossref
Sabrina Storgaard Sørensen, Kjeld Møller Pedersen, Ulla Møller Weinreich & Lars Ehlers. (2016) Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease. Applied Health Economics and Health Policy 15:3, pages 413-424.
Crossref
Crossref
Christine G. KohnSimon B. ZeichnerQiushi ChenAlberto J. MonteroDaniel A. GoldsteinChristopher R. Flowers. (2017)
Cost-Effectiveness of Immune Checkpoint Inhibition in
BRAF
Wild-Type Advanced Melanoma
. Journal of Clinical Oncology 35:11, pages 1194-1202.
Crossref
Crossref
Megan A. Bohensky, Kumar Pasupathi, Alexandra Gorelik, Hansoo Kim, James P. Harrison & Danny Liew. (2016) A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. Value in Health 19:8, pages 1009-1015.
Crossref
Crossref
Patrizio Caturegli, Giulia Di Dalmazi, Martina Lombardi, Federica Grosso, H. Benjamin Larman, Tatianna Larman, Giacomo Taverna, Mirco Cosottini & Isabella Lupi. (2016) Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade. The American Journal of Pathology 186:12, pages 3225-3235.
Crossref
Crossref
Beatriz Guglieri-López, Alejandro Pérez-Pitarch, Begoña Porta Oltra, Francisco Ferriols-Lisart, Ángeles Royo-Peiró & Mónica Climente-Martí. (2016) Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting. Anti-Cancer Drugs 27:7, pages 679-684.
Crossref
Crossref
F. Bernard-Arnoux, M. Lamure, F. Ducray, G. Aulagner, J. Honnorat & X. Armoiry. (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-Oncology 18:8, pages 1129-1136.
Crossref
Crossref
Nataniel H. Lester-Coll, Charles E. Rutter, Trevor J. Bledsoe, Sarah B. Goldberg, Roy H. Decker & James B. Yu. (2016) Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. International Journal of Radiation Oncology*Biology*Physics 95:2, pages 663-672.
Crossref
Crossref
Maria De Francesco, Mark Lamotte, Paolo Antonio Ascierto, Paolo Di Rienzo & Yumi Asukai. (2016) Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 3:2, pages GRHTA.5000230.
Crossref
Crossref
Patrick J. Medina & Val R. Adams. (2016) PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:3, pages 317-334.
Crossref
Crossref
J. Zaragoza, A. Caille, N. Beneton, G. Bens, F. Christiann, H. Maillard & L. Machet. (2015) High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. British Journal of Dermatology 174:1, pages 146-151.
Crossref
Crossref
Isabelle Tromme, Catherine Legrand, Brecht Devleesschauwer, Ulrike Leiter, Stefan Suciu, Alexander Eggermont, Julie Francart, Frederic Calay, Juanita A. Haagsma, Jean-Fran?ois Baurain, Luc Thomas, Philippe Beutels & Niko Speybroeck. (2016) Melanoma burden by melanoma stage: Assessment through a disease transition model. European Journal of Cancer 53, pages 33-41.
Crossref
Crossref
S. Valpione, C. Martinoli, P. Fava, S. Mocellin, L.G. Campana, P. Quaglino, P.F. Ferrucci, J. Pigozzo, C. Astrua, A. Testori & V. Chiarion-Sileni. (2015) Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. European Journal of Cancer 51:14, pages 2086-2094.
Crossref
Crossref
Taehwan Park, Scott K. Griggs & Dong-Churl Suh. (2015) Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review. BioDrugs 29:4, pages 259-274.
Crossref
Crossref
Yonghong Li, Lance A. Bare, Richard A. Bender, John J. Sninsky, Leslie S. Wilson, James J. Devlin & Frederic M. Waldman. (2015) Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Molecular Diagnosis & Therapy 19:3, pages 169-177.
Crossref
Crossref